Evidence map›Paper›PMID 41800141›Full record

ArticleBiomaterials research2026

Near-Infrared Responsive Nanoplatform for Synergistic Photothermal Therapy/Chemotherapy of Lung Cancer.

Kangqi Ren, Jian Wang, Lei Xue, Jieyu Liu, Jun Li, Degang Liu, Qiang Yang, Jiangzhou Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kangqi RenDepartment of Thoracic Surgery, The Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen 518020, China.
Jian WangDepartment of Thoracic Surgery, The Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen 518020, China.
Lei XueDepartment of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.
Jieyu LiuDepartment of Thoracic Surgery, The Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen 518020, China.
Jun LiDepartment of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.
Degang LiuDepartment of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.
Qiang YangDepartment of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.
Jiangzhou PengDepartment of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.ORCID https://orcid.org/0000-0002-8058-8988

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is one of the most prevalent and lethal solid tumors worldwide. Traditional treatment methods mainly rely on chemotherapeutic drugs, which kill tumor cells by inhibiting their mitosis and proliferation. However, in clinical practice, first-line chemotherapeutic agents often exhibit short half-lives and induce a range of adverse reactions while potentially leading to tumor cell resistance, significantly reducing therapeutic efficacy. To address these issues, we developed a novel nanoplatform (TSPD), which used titanium dioxide (TiO

Identifiers

PMID41800141
PMCPMC12963644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.